AG890

AG890 is an investigational, low-dose, progestin-only contraceptive transdermal patch being developed by Agile Therapeutics for women who are unable or unwilling to use estrogen-containing hormonal contraception, including breastfeeding women. It delivers levonorgestrel via Agile’s proprietary once-weekly Skinfusion transdermal technology, which uses an active and peripheral adhesive system to provide stable seven-day drug delivery and dependable adhesion. By providing continuous progestin exposure without estrogen, AG890 is intended to inhibit ovulation and thicken cervical mucus to prevent pregnancy, offering a convenient, weekly, estrogen-free contraceptive option that expands choices for women with contraindications or preferences against estrogen therapy.[1][3][5][8][9][11][15]